Essential thrombocytosis: Difference between revisions

(Text replacement - "* " to "*")
No edit summary
 
Line 1: Line 1:
==Background==
==Background==
*Rare, chronic myeloproliferative neoplasm
*Rare, chronic [[myeloproliferative disorders|myeloproliferative neoplasm]]
*Abnormal proliferation is seen in megakaryocytic line only
*Abnormal proliferation is seen in megakaryocytic line only
*Typically in elderly
*Typically in elderly
Line 6: Line 6:


==Clinical Features==
==Clinical Features==
*Leukocytosis
*[[Leukocytosis]]
*Anemia
*[[Anemia]]
*Splenomegaly
*Splenomegaly
*Clotting or bleeding
*Clotting or [[coagulopathy|bleeding]]


==Differential Diagnosis==
==Differential Diagnosis==
Line 15: Line 15:
*[[Chronic myelogenous leukemia]] (CML)
*[[Chronic myelogenous leukemia]] (CML)
*[[Polycythemia vera]] (PV)
*[[Polycythemia vera]] (PV)
===Reactive thrombocytosis===
* Acute [[hemorrhage|blood loss]]
* Acute [[hemolytic anemia]]
* Iron deficiency [[anemia]]
* Treatment of [[vitamin B12 deficiency]]
* Rebound effect after [[thrombocytopenia]] treatment
* Metastatic cancer
* [[Lymphoma]]
* Rheumatologic disorders
* [[IBD]]
* Celiac disease
* [[Kawasaki disease]]
* [[Nephrotic syndrome]]
* POEMS syndrome
* Thermal [[burn]]
* [[MI]]
* Severe [[trauma]]
* [[Acute pancreatitis]]
* Post-surgery, especially [[splenectomy]]
* CABG
* [[TB]]
* Acute [[bacterial disease|bacterial]]/[[viruses|viral]] infections
* [[asplenic patient|Asplenia]]
* [[Allergic reaction]]
* Medication reactions: vincristine, [[epinephrine]], [[glucocorticoids]], IL-1B, ATRA, thrombopoietin, [[LMWH]]<ref>uptodate</ref>
===Autonomous thrombocytosis===
* [[Essential thrombocytosis]]
* [[Polycythemia vera]]
* Mixed [[myelodysplastic syndrome|myelodysplastic]] and/or [[myeloproliferative disorders|myeloproliferative syndrome]]
===Spurious (false) thrombocytosis===
* Mixed cryoglobulinemia
* Cytoplasmic fragments
* [[Bacteremia]]


==Evaluation==
==Evaluation==
Line 40: Line 75:


==Management==
==Management==
*ASA 81mg
*[[ASA]] 81mg
*Myelosuppressive agents (hydroxyurea, interferon alpha)
*Myelosuppressive agents ([[hydroxyurea]], Interferon-α)
*Anagrelide
*Anagrelide



Latest revision as of 00:27, 1 October 2019

Background

  • Rare, chronic myeloproliferative neoplasm
  • Abnormal proliferation is seen in megakaryocytic line only
  • Typically in elderly
  • Generally asymptomatic

Clinical Features

Differential Diagnosis

Reactive thrombocytosis

Autonomous thrombocytosis

Spurious (false) thrombocytosis

  • Mixed cryoglobulinemia
  • Cytoplasmic fragments
  • Bacteremia

Evaluation

Workup

  • CBC
  • Chem 7
  • ESR
  • Bone marrow biopsy sometimes needed

Evaluation[2]

Per the WHO guidelines, diagnosis of ET requires all of the following:

Major criteria
Thrombocytosis ≥ 450 x 109L
Megakaryocyte proliferation with little to no granulocyte or erythroid proliferation
Not meeting criteria for CML, PV, PMF, MDS or other myeloid neoplasm
No evidence of reactive thrombocytosis or presence of JAK2V617F or other clonal marker

Management

  • ASA 81mg
  • Myelosuppressive agents (hydroxyurea, Interferon-α)
  • Anagrelide

Disposition

Also See

References

  1. uptodate
  2. Tefferi, A, et al. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009; 115(17):3842-7,